PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Foamix Ltd

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Foamix Receives a New U.S Patent for its Emollient and Aqueous Foam Technology - The patent covers foams with Urea, Lactic Acid, Salicylic Acid and penetration enhancers
Foamix Receives a New U.S Patent for its Emollient and Aqueous Foam Technology

 

NewswireToday - /newswire/ - Rehovot, Israel, 2010/04/29 - The patent covers foams with Urea, Lactic Acid, Salicylic Acid and penetration enhancers.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Foamix Ltd, a leading developer of topical products, which can be used for dermatological, gynecological and ophthalmic applications, today announced that the United States Patent Office has granted the company a new patent on its Emollient and Aqueous Foam technology platforms.

United States Patent No. 7,700,076, entitled “Penetrating pharmaceutical foam” covers unique emollient foam compositions and aqueous foam compositions that can be used to deliver a wide range of actives having activity against many diseases and disorders.
"Foamix continually strives to strengthen and expand its intellectual property position, which is a key aspect to our business and competitive position. The grant of this U.S. patent is the result of extensive ongoing efforts to develop a stream of innovative products and technologies for the dermatology and gynecology markets that provide enhanced efficacy and consumer satisfaction," said Dr. Dov Tamarkin, CEO of Foamix.

The patent claims foam compositions comprising urea, alpha-hydroxy acids (such as lactic acid and glycolic acid) and beta-hydroxy acids, e.g., salicylic acid, which are keratolytic.

The granted claims are further directed to foam compositions that contain skin penetration enhancers, including inter alia propylene glycol, glycerol, dimethyl isosorbide, and certain polyethylene glycol PEG polymers. The claims also cover a variety of drugs that can additionally be incorporated in such compositions, including antibacterial agents, antifungals, antiviral agents, corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs), anti-allergic agents, anticancer agents, local anesthetics, retinoids, photodynamic therapy agents, anti-wrinkle agents, skin whitening agents, immunosuppressants and immunomodulators.

About Foamix Ltd

Headquartered in Rehovot, Israel, Foamix Ltd (foamix.co.il) is a leading developer of topical foam and Oil Gel™ formulations, which can be used for dermatological, gynecological and ophthalmic applications. Foamix’s state-of-the-art foams and OilGel™ formulations provide controlled delivery of a variety of active ingredients. Foamix is currently collaborating with pharmaceutical and cosmetic companies on a range of projects in the development of proprietary dermatological and gynecologic foam products. Additionally, the Company has an in-house pipeline of dermatological and gynecological formulations in foam presentation.

To date, Foamix has twenty two issued patents worldwide covering its foam and OilGel™ technology platforms, including 8 issued patents in the United States. The company further has over 150 pending patent applications worldwide, of which more than 50 are filed in the U.S.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Foamix Ltd

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Foamix Receives a New U.S Patent for its Emollient and Aqueous Foam Technology

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Dov Tamarkin - Foamix.co.il 
+972 8 9316233 dov[.]foamix.co.il
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Foamix Ltd securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Foamix Ltd / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

FDA Approves Genentech’s Actemra (Tocilizumab) for Giant Cell Arteritis
BTG and HealthLoop Collaborate on IO Loop™ - An Exclusive Service to Connect Patients and Interventional Oncologists throughout Treatment
BD and UniteOR Join Forces to Deliver an Integrated Tracking Solution for the Operating Room Setting
MDxHealth and Maastricht University Collaborate on Next Generation (Epi)genetic Cancer Diagnostics
BD to Invest $60 Million in Nebraska Manufacturing Facility
MDxHealth Announces New Contract with MediNcrease Health Plans Regarding ConfirmMDx and SelectMDx
Pulse Certified As A Level Four Multichannel Content Agency by Veeva
Earthly Mist - Opioid-Alternative Painkiller, Kratom Now Available in Oklahoma City
MDxHealth and Exact Sciences Sign Collaboration Agreement
BD Advances Efforts to Combat Antimicrobial Resistance with Enhanced Diagnostic Solution Offering
First European Patients Treated with DC Bead LUMI™ Radiopaque Drug-Eluting Beads
FDA Approves Genentech’s Lucentis (Ranibizumab Injection) for Diabetic Retinopathy
Biopharmaceutical Analytical Instrumentation Market Garners Strong Opportunities from Double-digit Growth in Biosimilars Finds Frost & Sullivan
BD Completes Acquisition of Caesarea Medical Electronics
MDxHealth and Ghent University Ink Licensing and Collaboration Agreements to Develop Cancer Biomarker Visualization Technology

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit  JobsWare.com





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)